Royalty Pharma plc RPRX
68.68 USD +0.16 (+0.23%)
Regular-session close
68.68 0.00 0.00%
After hours · Nov 17, 4:33 PM ET
67.62 Day range 68.77
37.31 52-week range 70.37
- YTD
- +77.74%
- 1 year
- +75.38%
News
seekingalpha.com Royalty Pharma plc (RPRX) Presents at UBS Global Biopharma Conference 2026 Transcript Royalty Pharma plc (RPRX) Presents at UBS Global Biopharma Conference 2026 Transcript
benzinga.com Here's How Much $100 Invested In Royalty Pharma 15 Years Ago Would Be Worth Today Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 15 years by 6.93% on an annualized basis producing an average annual return of 19.95%. Currently, Royalty Pharma has a market…
globenewswire.com Royalty Pharma to present at the UBS Global Biopharma Conference NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the UBS Global Biopharma Conference on Tuesday, November…
seekingalpha.com Royalty Pharma: Stronger Royalty Growth Supports Further Upside Royalty Pharma's Q3 royalty receipts increased 9% to $883 million, led by strong growth in Tremfya, Voranigo, and Evrysdi. Vertex now accounts for approximately 25% of royalty receipts, indicating…
247wallst.com 3 Biotech Stocks That Actually Pay Dividends and Keep Raising Them Biotech usually torches cash and dilutes shareholders to fund the next trial. Three drugmakers flip that script, and the one with the smallest yield may be hiding the sturdiest payout of all.benzinga.com Citigroup Maintains Buy on Royalty Pharma, Raises Price Target to $78 Citigroup analyst Geoff Meacham maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $70 to $78.
benzinga.com Royalty Pharma Q3 Adj. EPS $1.21 Beats $1.18 Estimate, Sales $690.000M Miss $796.528M Estimate Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $1.21 per share which beat the analyst consensus estimate of $1.18 by 2.54 percent. This is a 3.42 percent increase over earnings of $1.17…
benzinga.com Here's How Much $100 Invested In Royalty Pharma 10 Years Ago Would Be Worth Today Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 10 years by 32.09% on an annualized basis producing an average annual return of 45.51%. Currently, Royalty Pharma has a market…
benzinga.com ARM, McDonald's On Deck Wednesday As AI Demand, Consumer Spending Face Test ARM Holdings headlines Wednesday’s reports, with investors looking for evidence that AI-related demand can support the chip designer after a sharp stock pullback. McDonald’s, Novo Nordisk, Uber…
